AI-based analysis of tumor pathology slides can predict immunotherapy outcomes in rare cancers, according to a recent MD Anderson study.
Key Details
- 1MD Anderson researchers applied AI to analyze pathology slides from rare cancer patients undergoing immunotherapy.
- 2The AI tool rapidly quantified immune cell infiltration and tumor content using routine pathology slides.
- 3Combined metrics (immune infiltration increase and tumor content decrease) strongly predicted positive immunotherapy response.
- 4Patients with favorable markers had a 64% lower risk of progression or death and nearly quadrupled median survival (42 vs. 10 months).
- 5Study funded by Merck, with AI analysis support from Lunit.
- 6Further validation in larger cohorts is necessary before clinical adoption.
Why It Matters
This study demonstrates AI's potential to extract actionable insights from standard pathology, enabling tailored immunotherapy decisions for rare cancer patients. If validated, such approaches could significantly improve outcomes using data already collected in clinical workflows.
Source
EurekAlert
Related News
•EurekAlert
AI Framework Accelerates Aortic Aneurysm Risk Prediction from Imaging
Researchers developed BioPINN-LM, combining physics-informed neural networks and multimodal large language models to deliver fast, interpretable risk assessments for ascending thoracic aortic aneurysms.
•EurekAlert
Study Finds Patient Voices Missing in Generative AI Design for Oncology
A Flinders University-led review found patients and carers are rarely involved in shaping generative AI tools used in oncology.
•EurekAlert
Scripps Researchers Develop AI Foundation Model for ECG-Based Heart Disease Prediction
A new AI foundation model, ECG-CLIP, improves detection and prediction of multiple heart diseases using large-scale ECG and clinician note data.